Yogiyo cuts marketing spend despite competition from rivals Delivery Hero’s Korean arm turned profitable but potential buyers are not optimistic
Translated by Ryu Ho-joung 공개 2021-04-12 08:20:02
이 기사는 2021년 04월 12일 08:17 thebell 에 표출된 기사입니다.
Yogiyo, Delivery Hero’s South Korean unit, has reduced its marketing efforts over the last year despite rivals continuing to heavily invest to expand their share in the burgeoning food delivery market, raising questions among potential buyers of the company.Yogiyo’s gross merchandise value (GMV) grew 59% to 2.9 trillion won ($2.6 billion) in 2020, according to an information memorandum sent to prospective buyers. Revenue also increased 53% to 353 billion won in the same period.
Notably, its earnings before interest, tax, depreciation and amortization turned positive to 47 billion won, compared to negative 60 billion won a year earlier.
The turnaround was due in large part to reduced marketing costs, which were down by 40 billion won compared to 2019. This is raising questions among potential buyers of Yogiyo as the company focused on profitability instead of growth as opposed to its rivals, which are aggressively increasing spending to bolster their presence in the fast-growing food delivery market.
Baedal Minjok, the largest player in the market, recorded GMV of 15.6 trillion won and revenue of 1.2 trillion won last year, up 73% and 102% year-on-year respectively. However, it still had an operating loss of 11.2 billion won.
Delivery Hero earlier this year accepted the Korea Fair Trade Commission’s ruling that approved the German company’s acquisition of Woowa Brother’s Baedal Minjok on the condition that it divests from Yogiyo. The acquisition was completed last month.
“Yogiyo’s position as the second largest player in the country’s food delivery market is clearly attractive to investors,” said an official at one private equity firm in Seoul. “But the Woowa Brother deal has weakened Yogiyo’s competitive position and potential buyers will focus on that.”
The first round of bidding for the company is scheduled for May 4. Morgan Stanley is managing the sale. (Reporting by Se-hun Jo)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
best clicks
최신뉴스 in 전체기사
-
- [제일약품의 온코닉테라퓨틱 첫 '신약']세번째 P-CAB '자큐보' 2년만에 신약 명맥 잇는다
- 강동그룹, 디아너스CC 품는다
- [제약사 TSR 분석]제일약품, '주가·실적·배당' 3중고 열쇠 '온코닉의 신약'
- (여자)아이들 우기, 'YUQ1' 아이튠즈 앨범차트 10개국 석권
- 박셀바이오, 진행성 간세포암 타깃 'Vax-NK' 특허 출원
- 베니스 비엔날레, 30년만에 두발로 선 '곽훈'의 의미
- [대기업 프로스포츠 전술전략]'모기업발 숙제' 엔씨다이노스, 당분간 긴축 불가피
- 하이브, '민희진 없는' 어도어 경쟁력 입증할까
- SK 오너가 3세 최성환의 '승부수'
- 어느 수집가의 꿈 '이건희 컬렉션'